Horse Allo 20

RSS

allogeneic equine adipose-derived mesenchymal stem cells

Refused
This medicine was refused authorisation for use in the European Union.

Overview

On 21 June 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Horse Allo 20, intended for the treatment of lameness in adult horses with osteoarthritis.

On 24 January 2019, the CVMP revised part of its opinion but confirmed its recommendation to refuse the marketing authorisation.

The company that applied for authorisation is Centauri Biotech SL.

This EPAR was last updated on 12/09/2019

Application details

Product details
Name
Horse Allo 20
Active substance
allogeneic equine adipose-derived mesenchymal stem cells
International non-proprietary name (INN) or common name
allogeneic equine adipose-derived mesenchymal stem cells
Species
Horses
Application details
Marketing-authorisation applicant
Centauri Biotech SL
Date of opinion
21/06/2018
Date of refusal of marketing authorisation
13/05/2019

Assessment history

How useful was this page?

Add your rating